AMGN — Amgen
Data coverage, completeness and provenance for Amgen in the Stock Market API — Health Care · Drug Manufacturers - General.
Stored price coverage
Source date: 2026-11-19T21:00:01. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-11-19 | 438.8200 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-18 | 443.8900 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-17 | 457.9300 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-16 | 462.3200 | USD | yfinance | Split- and dividend-adjusted close |
| 2026-11-13 | 465.6700 | USD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/AMGN/prices · Price parameters and adjustment semantics
No archived filings are currently stored for this listing.
Profile
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Employees: 31,500 · Website: https://www.amgen.com · Profile fields populated: 75%
Data completeness by statement
Share of stored fields populated in the anchor reporting period (FY2025), primary source sec_edgar. Full per-field breakdown: GET /api/v1/companies/AMGN/financials.
Financial statement coverage (USD)
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2025 (USD) | 2025-12-31 | 32 | sec_edgar | ||||
| FY2024 (USD) | 2024-12-31 | 32 | sec_edgar | ||||
| FY2023 (USD) | 2023-12-31 | 32 | sec_edgar | ||||
| FY2022 (USD) | 2022-12-31 | 32 | sec_edgar | ||||
| FY2021 (USD) | 2021-12-31 | 32 | sec_edgar |
Get AMGN data via the API
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Company profile
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/AMGN
Financial statements
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/AMGN/financials
Computed ratios
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/AMGN/metrics/summary
News & announcements
Dated press releases and announcements with source links.
GET /api/v1/companies/AMGN/news
Quick start
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/AMGN
Query AMGN programmatically
Free tier — instant API key. Built for AI agents.
Other NASDAQ · Health Care companies covered
Frequently Asked Questions
- What data does the API provide for AMGN?
- Stored coverage for AMGN: price data available, financial statements available, 0 archived filings. REST endpoints are under /api/v1/companies/AMGN; inspect available source metadata for provenance.
- How complete is AMGN's financial data?
- The anchor reporting period (FY2025) has 100.0% of the 17 core statement fields populated. Primary source: sec_edgar.
- What reporting periods are covered for AMGN?
- 5 fiscal-year periods are stored (FY2021–FY2025), with per-period field counts and source tags available via /api/v1/companies/AMGN/financials.
- Where does AMGN's data come from?
- Stored price source: yfinance. Primary source for the statement snapshot: sec_edgar. Inspect available period and field source tags at /api/v1/companies/AMGN/financials; missing tags do not establish provenance.